Identity
Disease
Soft tissue tumour, presenting as a slow growing mass intimately associated with tendons and aponeuroses, in young adults. Note To be distinguished from clear cell sarcoma of the kidney, to which it is unrelated.
Embryonic origin
Mesoderm.
Epidemiology
Rare sarcoma affecting primarily young adults
Clinics
Slowly growing tumour mass, causing pain or tenderness, particularly frequently (up to 95% of the cases) situated in the extremities, with a predilection for the foot and the ankle.
Pathology
Polygonal or spindle shaped cells with abundant eosinophilic or clear cytoplasm displaying a uniform, nested to fascicular growth pattern, delineated by fibrous septa. Melanin deposits can be demonstrated using specific stains, but is more readily detectable by immunoreactivity against melanoma antigens (e.g. S100 and HMB45) in the vast majority of the cases.
Treatment
Radical surgical resection, adjuvant radiotherapy should be considered in incomplete resections, large (>5 cm) tumours and/or high grade lesions. Clear cell sarcomas seem to display little sensitivity to conventional soft tissue sarcoma multi-agent chemotherapy protocols.
Left to right: A: Typical clear cell sarcoma with eosinophilic cytoplasm (H&E, 400x); B: A reticulin meshwork surrounds the individual nests (reticulin, 200x); C: Strong S100 immunoreactivity, a consistent feature (S100, 400x).
Evolution
Special attention should be paid to the occurrence of late recurrences (median time to recurrence: 4.2 years).
Prognosis
Generally, clear cell sarcoma is characterised by an adverse prognosis, only 40 to 50% of the patients being long-term survivors. As recurrences may occur late, 5-year survival rates tend to misjudge prognosis. Established prognostic features include: tumour size, necrosis and local recurrence.
Cytogenetics
The t(12;22)(q13;q12), as identified by G-banding.
Cytogenetics Morphological
The cytogenetic hallmark of clear cell sarcoma is the presence of the t(12;22)(q13;q12). This translocation has been described in the majority of reported clear cell sarcoma cases, not however in other malignancies. The translocation is readily identifiable with G-, R-or Qbanding.
Cytogenetics Molecular
Fluorescence in situ hybridisation based approaches can be used to demonstrate the t(12;22), using chromosome painting probes or to demonstrate EWSR1 and ATF1 gene rearrangement, using gene specific probes.
Dual colour in situ hybridisation the EWS cosmid G9 (green) and the ATF1 CCS2.2 cosmid (red) demonstrating a juxtaposition of 5' EWS to 3' ATF1 sequences, indicating the presence of a EWS/ATF1 genomic fusion (arrowheads).
Probes
EWSR1 probes: 5' EWSR1: G9 cosmid; 3' ATF1 probe: CCS2.2
Additional anomalies
Although the t(12;22) has been reported as the sole chromosomal aberration in clear cell sarcoma, most cases display additional cytogenetic anomalies, including +7, +8 and structural and numerical aberrations of chromosome 22.
Variants
No variant translocations, creating EWSR1/ATF1 fusion transcripts, have been described. 
Genes involved and proteins

EWSR1
ATF1
Location 12q13 DNA / RNA ATF1 is transcribed from centromere to telomere at 12q13. The coding sequence contains 816 bp, comprising 6 exons and spans approximately 43 kb. Protein ATF1 encodes a member of the CREB/ATF basic leucine-zipper type transcription factor family and binds to cAMP inducible promotors.
Result of the chromosomal anomaly
Hybrid Gene
Description
The EWS/ATF1 fusion transcript is detectable in up to 90% of the clear cell sarcoma cases. As described in other EWS rearrangements, the transcript fuses 5' EWS to 3' heterologous sequences. The reciprocal ATF1/EWS fusion probably does not contribute to malignant transformation since it is out of frame. Transcript Several alternatively spliced transcripts have been described, the more frequent being the type 1 fusion: EWS exon 8 fused to ATF1 exon 4.
Fusion Protein
Oncogenesis
The EWS/ATF1 oncoprotein converts ATF1 to a constitutive transcriptional activator that represses p53/CBP-mediated transactivation.
Detection protocole: as described by Antonescu et al. (the data given are virtually identical to the Table 1 from the mentioned reference).
